Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies

Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the exclusive license of potential monoclonal antibodies from Curia Global, a leading contract research, development and manufacturing organization.

Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.

Contact Details

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.